lobbying_activities: 1519209

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1519209	2419d881-784a-4aca-b5c3-9d6ce269b8cb	Q1	BROWN RUDNICK LLP	287895	AMNEAL PHARMACEUTICALS	2014	first_quarter	PHA	Issues related to FDA rule on drug labeling; issues relating to Risk Evaluation and Mitigation Strategies; Drug Quality and Security Act ( P.L. 113-54); FDA Proposed Rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (RIN:0910-AG94).	Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE	30000		0	0	2014-04-16T14:34:31.833000-04:00